As drug target reemerges, the question is to block or stimulate it
More than two decades ago, drugmakers searching for new hypertension medications unearthed a mysterious new cell receptor that responded to a hormone known as angiotensin II. This peptide hormone constricts blood vessels, but, oddly, blocking the so-called angiotensin II receptor type 2 (AT2) appeared to have no effect on blood pressure, so the target was largely ignored by drug developers. “Big pharma really just left the AT2 receptor by the side of the road,” says Tom McCarthy, chief executive of Spinifex Pharamceuticals, a company based in Melbourne, Australia, that is exploring the promise of targeting AT2. Read more
Recent comments
Real-time tissue analysis could guide brain tumor surgery
Bundled RNA balls silence brain cancer gene expression
Ebola outbreak in West Africa lends urgency to recently-funded research